NO164030B - PROCEDURE TE FOR PREPARING IMIDAZO RIFAMYCINTER. - Google Patents
PROCEDURE TE FOR PREPARING IMIDAZO RIFAMYCINTER. Download PDFInfo
- Publication number
- NO164030B NO164030B NO851920A NO851920A NO164030B NO 164030 B NO164030 B NO 164030B NO 851920 A NO851920 A NO 851920A NO 851920 A NO851920 A NO 851920A NO 164030 B NO164030 B NO 164030B
- Authority
- NO
- Norway
- Prior art keywords
- rifamycin
- mol
- pyridine
- formula
- amino
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 48
- BTVYFIMKUHNOBZ-ZDHWWVNNSA-N Rifamycin S Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C BTVYFIMKUHNOBZ-ZDHWWVNNSA-N 0.000 claims description 22
- BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 claims description 22
- 229910052740 iodine Inorganic materials 0.000 claims description 21
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 19
- 239000011630 iodine Substances 0.000 claims description 19
- 239000011541 reaction mixture Substances 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims description 13
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 8
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 239000007800 oxidant agent Substances 0.000 claims description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 4
- 239000012429 reaction media Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000003222 pyridines Chemical class 0.000 claims description 2
- 229940081192 rifamycins Drugs 0.000 claims 1
- 239000000047 product Substances 0.000 description 28
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 16
- HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 description 14
- 229940109171 rifamycin sv Drugs 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 235000010323 ascorbic acid Nutrition 0.000 description 12
- 229960005070 ascorbic acid Drugs 0.000 description 12
- 239000011668 ascorbic acid Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 11
- 229950011175 aminopicoline Drugs 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- 230000007935 neutral effect Effects 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 238000002329 infrared spectrum Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 229930189077 Rifamycin Natural products 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- -1 for example Chemical group 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- 229960003292 rifamycin Drugs 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WJMJWMSWJSACSN-UHFFFAOYSA-N 3,5-dibromopyridin-2-amine Chemical compound NC1=NC=C(Br)C=C1Br WJMJWMSWJSACSN-UHFFFAOYSA-N 0.000 description 1
- OCWBGKZFOYMCCN-UHFFFAOYSA-N 3,5-dichloropyridin-2-amine Chemical compound NC1=NC=C(Cl)C=C1Cl OCWBGKZFOYMCCN-UHFFFAOYSA-N 0.000 description 1
- RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 1
- MAXBVGJEFDMHNV-UHFFFAOYSA-N 5-chloropyridin-2-amine Chemical compound NC1=CC=C(Cl)C=N1 MAXBVGJEFDMHNV-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- OSILBMSORKFRTB-UHFFFAOYSA-N isoquinolin-1-amine Chemical compound C1=CC=C2C(N)=NC=CC2=C1 OSILBMSORKFRTB-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- SQTCRTQCPJICLD-KTQDUKAHSA-N rifamycin B Chemical compound OC1=C(C(O)=C2C)C3=C(OCC(O)=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O SQTCRTQCPJICLD-KTQDUKAHSA-N 0.000 description 1
- SQTCRTQCPJICLD-OQQFTUDCSA-N rifomycin-B Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(OCC(=O)O)c4c3C2=O SQTCRTQCPJICLD-OQQFTUDCSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 1
Landscapes
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Foreliggende oppfinnelse angår en ny fremgangsmåte for fremstilling av imidazo-rifamycin-derivater med den generelle formel The present invention relates to a new method for the production of imidazo-rifamycin derivatives with the general formula
hvor R er acetyl, R^og R2uavhengig av hverandre, utgjør hydrogen, (C^_^)-alkyl eller halogen, eller hvor R^og R2sammen med to påfølgende karbonatomer i pyridinkjernen, danner en benzenring. where R is acetyl, R^ and R2 independently form hydrogen, (C^_^)-alkyl or halogen, or where R^ and R2 together with two consecutive carbon atoms in the pyridine nucleus form a benzene ring.
I denne sammenheng angir uttrykket (C^^)-alkyl en rettkjedet eller forgrenet alkylgruppe som f.eks.- metyl, In this context, the term (C^^)-alkyl denotes a straight-chain or branched alkyl group such as, for example, methyl,
etyl, propyl, isopropyl, butyl, sek.-butyl, isobutyl og tert.-butyl. ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl and tert-butyl.
Noen av forbindelsene med formel I, dvs. forbindelser hvor R er acetyl og R^og R2uavhengig av hverandre er hydrogen eller (C1_^)-alkyl, eller hvor R2og R2sammen med to påfølgende karbonatomer i pyridinkjernen, danner en benzenring, er kjent fra litteraturen, se US-patent 4341785 av 27. juli, 1982. Some of the compounds of formula I, i.e. compounds where R is acetyl and R^ and R2 independently of each other are hydrogen or (C1_^)-alkyl, or where R2 and R2, together with two consecutive carbon atoms in the pyridine nucleus, form a benzene ring, are known from the literature , see US Patent 4,341,785 dated July 27, 1982.
Andre forbindelser med formel I, dvs. forbindelser hvor R er acetyl og minst én av R^eller R2står for halogen, Other compounds of formula I, i.e. compounds where R is acetyl and at least one of R^ or R2 stands for halogen,
er beskrevet i utlagt italiensk patentsøknad nr. 3626 A/82. is described in published Italian patent application No. 3626 A/82.
I disse to publikasjoner er det også beskrevet en fremgangsmåte for fremstilling av forbindelser med formel I. In these two publications, a method for preparing compounds of formula I is also described.
De kjente fremgangsmåter går i korthet ut på å omsette en molar mengde av et 3-halogen-rifamycin S med formel hvor R betyr acetyl, og halo fortrinnsvis står for brom eller jod, med 2-8 molekvivalenter av et passende 2-amino-pyridin med formel Briefly, the known methods involve reacting a molar amount of a 3-halo-rifamycin S of formula where R means acetyl, and halo preferably stands for bromine or iodine, with 2-8 molar equivalents of a suitable 2-amino-pyridine with formula
eller et salt derav. or a salt thereof.
En forbindelse med formel ble herunder oppnådd. Etter isolering og karakterisering, ble den deretter behandlet med ascorbinsyre for å gi sluttproduktet med formel I. A compound of formula was obtained below. After isolation and characterization, it was then treated with ascorbic acid to give the final product of formula I.
Utbyttet i de angitte trinn, beregnet på basis av utgangsforbindelsen IV, er iblant ganske bra (varierende fra 45 % til 75 %), men fremgangsmåten beskrevet i US-patentet har den betydelige svakhet at utgangsforbindelsen IV ikke er kommersielt tilgjengelig. Den må derfor fremstilles ved å gå ut fra rifamycin S ved en passende, ofte problemfylt, halo-generingsprosess. På grunn av dette gir fremgangsmåtene beskrevet i US-patent 4341785 og i den verserende italienske patentsøknad nr. 3626 A/82 meget lavere totalutbytte av forbindelse I enn de nevnte prosentangivelser, hvorved det ikke er mulig å oppnå de ønskede produkter i tilfredsstillende utbytte sett fra et industrielt synspunkt. The yield in the stated steps, calculated on the basis of the starting compound IV, is sometimes quite good (ranging from 45% to 75%), but the method described in the US patent has the significant weakness that the starting compound IV is not commercially available. It must therefore be prepared starting from rifamycin S by a suitable, often problematic, halo generation process. Because of this, the methods described in US Patent 4341785 and in the pending Italian Patent Application No. 3626 A/82 give much lower total yields of compound I than the mentioned percentages, whereby it is not possible to obtain the desired products in satisfactory yields from an industrial point of view.
Forbindelsene med formel I har fremragende antibakterielle egenskaper både in vitro og in vivo. De har spesielt vist seg å være anvendelige ved bekjempelse av gastrointestinale mikrobielle infeksjoner på grunn av deres lave absorbsjon i dyreorganer og vev når de gis peroralt. The compounds of formula I have excellent antibacterial properties both in vitro and in vivo. They have been particularly found to be useful in combating gastrointestinal microbial infections due to their low absorption in animal organs and tissues when administered orally.
Fremgangsmåten i henhold til foreliggende oppfinnelse representerer en betydelig forbedring i forhold til tidligere kjente metoder. Rifamycin S med formel The method according to the present invention represents a significant improvement in relation to previously known methods. Rifamycin S with formula
benyttes som utgangs-rifamycin-substrat. Dette er et kommersielt produkt som lett kan oppnås enten ved kjemisk omdannelse av rifamycin B, som beskrevet i fransk patent FM 739, ved sur hydrolyse av rifamycin 0, som beskrevet i belgisk patent 820517, eller ved oksydasjon av halomyciner med salpetersyrling, som beskrevet i US-patent 3880839, eller ved fermentering av Mikromonospora Chalcea-stammer, som beskrevet i US-patent 3884763. Forbindelsen omsettes med et molart overskudd av et 2-aminopyridin med formel is used as starting rifamycin substrate. This is a commercial product which can easily be obtained either by chemical transformation of rifamycin B, as described in French patent FM 739, by acid hydrolysis of rifamycin 0, as described in Belgian patent 820517, or by oxidation of halomycins with nitric acid, as described in US patent 3880839, or by fermentation of Mikromonospora Chalcea strains, as described in US patent 3884763. The compound is reacted with a molar excess of a 2-aminopyridine of formula
hvor og R2 har de ovenfor angitte betydninger, i nærvær av jod eller av et passende jodid/oksydasjonsmiddel-system, eventuelt i nærvær av en organisk eller uorganisk sur forbindelse, ved en temperatur i området mellom romtemperatur og reaksjonsblandingens kokepunkt, i et hensiktsmessig oppløsnings-middel eller oppløsningsmiddel-system, hvorpå de ønskede slutt-produkter gjenvinnes i utbytter på 60-80% beregnet på basis av det anvendte rifamycin S. where and R2 have the meanings given above, in the presence of iodine or of a suitable iodide/oxidizing agent system, optionally in the presence of an organic or inorganic acidic compound, at a temperature in the range between room temperature and the boiling point of the reaction mixture, in a suitable solvent agent or solvent system, whereupon the desired end products are recovered in yields of 60-80% calculated on the basis of the rifamycin S used.
Reaksjonen skjer således i ett trinn, som vist i det følgende reaks jonsskjema..... The reaction thus takes place in one step, as shown in the following reaction ion diagram.....
I praksis blir en molar mengde rifamycin S med formel II omsatt med1-8, fortrinnsvis 3-6, molekvivalenter 2-amino-pyridin med formel III, eventuelt i nærvær av en sur organisk eller uorganisk forbindelse, som f. eks. hydrogenjodidsyre eller eddiksyre, i nærvær av jod eller et korresponderende jodid/oksydasjonsmiddel-system, hvor jodidet for eksempel kan være jodidet av et alkali- eller jordalkali-metall eller hydro-jodidet av 2-aminopyridinet, og oksydasjonsmidlet kan være et middel som under de anvendte reaksjonsbetingelser, kan oksydere jodid-ionet til jod i reaksjonsmiljøet. In practice, a molar amount of rifamycin S with formula II is reacted with 1-8, preferably 3-6, molar equivalents of 2-amino-pyridine with formula III, optionally in the presence of an acidic organic or inorganic compound, such as e.g. hydroiodic acid or acetic acid, in the presence of iodine or a corresponding iodide/oxidizing agent system, where the iodide may for example be the iodide of an alkali or alkaline earth metal or the hydroiodide of 2-aminopyridine, and the oxidizing agent may be an agent which under the reaction conditions used, can oxidize the iodide ion to iodine in the reaction environment.
Jod eller jodid/oksydasjonsmiddel-systemet kan anvendes Iodine or the iodide/oxidizing agent system can be used
i reaksjonsmediet i mengder varierende fra 0,1 til 4 molekvivalenter pr. mol utgangs-rifamycin S eller i mengder som kan frigjøre fra 0,1 til 4 molekvivalenter jod pr. mol utgangs-rifamycin S. Reaksjonen utføres i et oppløsningsmiddel eller oppløsningsmiddel-system valgt blant dem som vanligvis benyttes innen rifamycin-feltet. Det kan således f. eks. benyttes lavere halogenerte hydrokarboner som metylenklorid, kloroform, 1,2-dikloretan og analoge forbindelser, eller lavere alkanoler så som metanol, etanol, propanol, isopropanol eller 4-butanol. Også lavere alkylestere av lavere alifatiske syrer, acetonitril, dimetoksyetan, dioksan, tetrahydrofuran og aroma-tiske hydrokarboner, har vist seg velegnet. Oppløsningsmidlene kan benyttes alene eller i blanding eller sammen med vann i ulike forhold. De beste resultater ble oppnådd med metylenklorid, acetonitril og dimetoksyetan. in the reaction medium in amounts varying from 0.1 to 4 molar equivalents per mol starting rifamycin S or in quantities which can release from 0.1 to 4 mole equivalents of iodine per mol starting rifamycin S. The reaction is carried out in a solvent or solvent system selected from those commonly used in the rifamycin field. It can thus e.g. lower halogenated hydrocarbons such as methylene chloride, chloroform, 1,2-dichloroethane and similar compounds, or lower alkanols such as methanol, ethanol, propanol, isopropanol or 4-butanol are used. Lower alkyl esters of lower aliphatic acids, acetonitrile, dimethoxyethane, dioxane, tetrahydrofuran and aromatic hydrocarbons have also proven suitable. The solvents can be used alone or in a mixture or together with water in various proportions. The best results were obtained with methylene chloride, acetonitrile and dimethoxyethane.
Reaksjonen utføres ved en temperatur i området mellom romtemperatur og reaksjonsblandingens kokepunkt. I alminnelighet er området mellom romtemperatur og 60°c tilstrekkelig for å oppnå de mest tilfredsstillende resultater. The reaction is carried out at a temperature in the range between room temperature and the boiling point of the reaction mixture. In general, the range between room temperature and 60°c is sufficient to achieve the most satisfactory results.
Reaksjonstiden avhenger av naturen av pyridin-substratet III, forholdet mellom reaktantene og av reaksjonstemperaturen. The reaction time depends on the nature of the pyridine substrate III, the ratio between the reactants and the reaction temperature.
I alminnelighet kreves fra 1 til 120 timer for å oppnå sluttproduktene I i ønsket utbytte. In general, from 1 to 120 hours are required to obtain the final products I in the desired yield.
Reaksjonsoppløsningen må siden behandles med et egnet reduksjonsmiddel som f. eks. ascorbinsyre, isoascorbinsyre eller dihydroksyaceton. Alle ovennevnte omsetninger skjer uten isolering av mellomproduktene slik at den typiske "ett-trinns-reaksjon" for fremgangsmåten i henhold til oppfinnelsen, bibe-holdes. De således oppnådde forbindelser med formel I isoleres fra reaksjonsmiljøet etter kjent teknikk. The reaction solution must then be treated with a suitable reducing agent such as e.g. ascorbic acid, isoascorbic acid or dihydroxyacetone. All of the above reactions take place without isolation of the intermediate products so that the typical "one-step reaction" for the method according to the invention is maintained. The thus obtained compounds of formula I are isolated from the reaction medium according to known techniques.
Således kan for eksempel overskuddet av uomsatt amino-pyridin med formel III, fjernes fra den organiske fase ved at den behandles med en vandig mineralsyreoppløsning. Den organiske fase skilles deretter fra, tørkes eventuelt over et egnet tørke-middel, f. eks. vannfri natriumsulfat, hvorpå sluttproduktet oppnås ved fordampning av oppløsningsmidlet. Som et alternativ kan de ønskede produkter oppnås ved krystallisasjon fra reaksjonsmediet ved en temperatur i området fra 0°C til 10°C dersom vannholdige oppløsningsmiddel-systemer benyttes. Thus, for example, the excess of unreacted amino-pyridine of formula III can be removed from the organic phase by treating it with an aqueous mineral acid solution. The organic phase is then separated, possibly dried over a suitable drying agent, e.g. anhydrous sodium sulfate, after which the final product is obtained by evaporation of the solvent. As an alternative, the desired products can be obtained by crystallization from the reaction medium at a temperature in the range from 0°C to 10°C if aqueous solvent systems are used.
Om nødvendig kan forbindelsene med formel I renses ved omkrystallisering fra egnede oppløsningsmidler eller opp-løsningsmiddel-systemer . If necessary, the compounds of formula I can be purified by recrystallization from suitable solvents or solvent-solvent systems.
I de etterfølgende eksempler er de angitte UV-spektra tatt opp i absolutt metanol med et Perkin-Elmer 552 spektrofotometer, IR-spektrene i KBr med et Perkin-Elmer 281-B spektrofotometer, In the following examples, the indicated UV spectra were recorded in absolute methanol with a Perkin-Elmer 552 spectrophotometer, the IR spectra in KBr with a Perkin-Elmer 281-B spectrophotometer,
1 13 1 13
mens kjernemagnetiske resonans-spektra, H-NMR og C-NMR, ble tatt opp i deuterokloroform med tetrametylsilan som intern standard ved hjelp av et Varian XL100 spektrofotometer. while nuclear magnetic resonance spectra, H-NMR and C-NMR, were recorded in deuterochloroform with tetramethylsilane as internal standard using a Varian XL100 spectrophotometer.
Eksempel 1 Example 1
4- deoksy- 4'- metyl- pyrido[ 1', 2' ;1, 2] imidazo[ 5, 4- c] rifamycin SV 4- deoxy- 4'- methyl- pyrido[ 1', 2' ; 1, 2] imidazo[ 5, 4-c] rifamycin SV
4,9 g (0,007 mol) rifamycin S, 2,27 g (0,021 mol) 2-amino-4-metyl-pyridin og 0,89 g (0,0035 mol) jod, ble løst opp i 30 ml metylenklorid og den resulterende reaksjonsblanding omrørt ved romtemperatur i 30 timer. Reaksjonsblandingen ble deretter tilsatt 5 ml 20 % (vekt/volum) vandig oppløsning av ascorbinsyre. 4.9 g (0.007 mol) of rifamycin S, 2.27 g (0.021 mol) of 2-amino-4-methyl-pyridine and 0.89 g (0.0035 mol) of iodine were dissolved in 30 ml of methylene chloride and the resulting reaction mixture stirred at room temperature for 30 hours. To the reaction mixture was then added 5 ml of a 20% (w/v) aqueous solution of ascorbic acid.
Etter omrøring i 30 minutter ble den organiske fase fraskilt og vasket med 0,5N vandig saltsyre og deretter med vann inntil nøytral reaksjon. Oppløsningsmidlet ble fordampet under vakuum og residuet krystallisert fra en blanding av etanol/vann, 7:3 (volumdeler). Etter filtrering og tørking ble det oppnådd 4,2 g produkt i et utbytte på 76 % av det teoretiske, som hadde følgende fysikalsk-kjemiske karakteristika: After stirring for 30 minutes, the organic phase was separated and washed with 0.5N aqueous hydrochloric acid and then with water until neutral reaction. The solvent was evaporated under vacuum and the residue crystallized from a mixture of ethanol/water, 7:3 (parts by volume). After filtration and drying, 4.2 g of product was obtained in a yield of 76% of the theoretical, which had the following physico-chemical characteristics:
IR- spektrum: karakteristiske absorbsjonsbånd ble registrert ved følgende frekvenser (i cm<-1>): 3440 (b), 2960 (s), 2920 (s), 2860 (w), 2820 (vw), 1705 <s), 1640 (s), 1580 (s) , 1500 (s) . IR spectrum: characteristic absorption bands were recorded at the following frequencies (in cm<-1>): 3440 (b), 2960 (s), 2920 (s), 2860 (w), 2820 (vw), 1705 <s), 1640 (s), 1580 (s) , 1500 (s) .
b = bred; s = sterk; w = svak; vw = meget svak. b = wide; s = strong; w = weak; vw = very weak.
1H- NMR- spektrum: karakteristiske resonanstopper ble registrert ved følgende 6 (uttrykt i ppm):. -0,56 (d, 3H) ; 0,14 (d, 3H) ; 0,74 (d, 3H); 0,94 (d, 3H); 1,94 (s, 3H); 1,98 (s, 3H); 2,02 (s, 3H); 2,26 (s, 3H); 2,63 (s, 3H); 3,00 (s, 3H); 3,2-3,9 1H-NMR spectrum: characteristic resonance peaks were recorded at the following 6 (expressed in ppm): -0.56 (d, 3H); 0.14 (d, 3H); 0.74 (d, 3H); 0.94 (d, 3H); 1.94 (s, 3H); 1.98 (s, 3H); 2.02 (s, 3H); 2.26 (s, 3H); 2.63 (s, 3H); 3.00 (p, 3H); 3.2-3.9
(m, 3H); 4,15-5,20 (m, 2H); 5,9-6,9 (m, 4H); 7,06 (dd, 1H); 7,38 (s, 1H) ; 8,39 (s, 1.H) ; 8,43 (d, 1H) ; 11,0 (s, 1H) ; (m, 3H); 4.15-5.20 (m, 2H); 5.9-6.9 (m, 4H); 7.06 (dd, 1H); 7.38 (s, 1H); 8.39 (p, 1.H) ; 8.43 (d, 1H); 11.0 (s, 1H);
13,12 (s, 1H) . 13.12 (p, 1H) .
s = singlet; d = dublett; m = multippel; dd = dobbelt dublett. 13 C- NMR- spektrum: karakteristiske resonanstopper ble registrert ved følgende 6 (uttrykt i ppm): 6,98; 8,06; 8,21; 10,76; 17,56; 20,43; 20,78; 21,44; 22,35; 32,91; 36,93; 37,78; 38,59; 56,99; 72,65; 73,91; 76,75; 77,86; 97,83; 103,86; 104,09; 108,97; 109,99; 112,03; 114,96; 115,52; 117,61; 119,26; 122,99; 125,35; 128,44; 128,96; 136,21; 138,87; 141,75; 142,10; 147,74; 155,10; 170,63; 171,89; 182,19; 188,84. s = singlet; d = doublet; m = multiple; dd = double duplicate. 13 C-NMR spectrum: characteristic resonance peaks were recorded at the following 6 (expressed in ppm): 6.98; 8.06; 8.21; 10.76; 17.56; 20.43; 20.78; 21.44; 22.35; 32.91; 36.93; 37.78; 38.59; 56.99; 72.65; 73.91; 76.75; 77.86; 97.83; 103.86; 104.09; 108.97; 109.99; 112.03; 114.96; 115.52; 117.61; 119.26; 122.99; 125.35; 128.44; 128.96; 136.21; 138.87; 141.75; 142.10; 147.74; 155.10; 170.63; 171.89; 182.19; 188.84.
Eksempel 2 Example 2
4- deoksy- 4'- metyl- pyrido[ 1', 2' :1, 2] imidazof 5, 4- c] rifamycin SV 4- deoxy- 4'- methyl- pyrido[ 1', 2' :1, 2] imidazof 5, 4-c] rifamycin SV
6,95 g (0,01 mol) rifamycin S og 3,24 g (0,03 mol) 2-amino-4-metyl-pyridin ble løst opp i 20 ml metylenklorid og reaksjonsblandingen tilsatt en oppløsning av 3,8 g (0,015 mol) jod i 100 ml metylenklorid under kraftig omrøring i løpet av 1 time. Reaksjonsblandingen ble omrørt i ytterligere 4 timer ved romtemperatur og deretter tilsatt 20 ml 20 % (vekt/volum) vandig oppløsning av ascorbinsyre. Omrøringen ble fortsatt i 30 min. til, hvorpå fasene ble adskilt og det organiske lag vasket med 0,5N vandig oppløsning av saltsyre og deretter med vann inntil nøytral reaksjon. Etter fordampning under vakuum av metylen-kloridet, ble det oppnådd et residuum som krystalliserte fra en blanding av etanol/vann, 7:3 (volumdeler) og ga 6,1 g produkt med samme fysikalsk-kjemiske karakteristika som forbindelsen beskrevet i Eksempel 1. Utbyttet var 78 % av det teoretiske. 6.95 g (0.01 mol) of rifamycin S and 3.24 g (0.03 mol) of 2-amino-4-methyl-pyridine were dissolved in 20 ml of methylene chloride and a solution of 3.8 g ( 0.015 mol) of iodine in 100 ml of methylene chloride with vigorous stirring during 1 hour. The reaction mixture was stirred for a further 4 hours at room temperature and then 20 ml of a 20% (w/v) aqueous solution of ascorbic acid was added. Stirring was continued for 30 min. to, whereupon the phases were separated and the organic layer washed with 0.5N aqueous solution of hydrochloric acid and then with water until neutral reaction. After evaporation under vacuum of the methylene chloride, a residue was obtained which crystallized from a mixture of ethanol/water, 7:3 (parts by volume) and gave 6.1 g of product with the same physico-chemical characteristics as the compound described in Example 1. The yield was 78% of the theoretical.
Eksempel 3 Example 3
3'- klor- 4- deoksy- pyridoC1', 2' :1, 2] imidazoC 5, 4- c] rifamycin SV 3'- chloro- 4- deoxy- pyridoC1', 2' :1, 2] imidazoC 5, 4- c] rifamycin SV
Ved i det vesentlige å benytte fremgangsmåten beskrevet i Eksempel 1 og gå ut fra 3,47 g (0,005 mol) rifamycin S, 1,54 g (0,012 mol) 2-amino-5-klorpyridin og 0,63 g (0,0025 mol) jod i 20 ml metylenklorid, ble 2,8 g av tittelproduktet oppnådd i et utbytte på 68 % av det teoretiske. By essentially using the method described in Example 1 and starting from 3.47 g (0.005 mol) rifamycin S, 1.54 g (0.012 mol) 2-amino-5-chloropyridine and 0.63 g (0.0025 mol) of iodine in 20 ml of methylene chloride, 2.8 g of the title product were obtained in a yield of 68% of the theoretical.
Forbindelsen oppviste følgende fysikalsk-kjemiske karakteristika: The compound showed the following physico-chemical characteristics:
IR- spektrum: karakteristiske absorbsjonsbånd ble registrert ved følgende frekvenser (i cm"<1>): 3430 (b), 3200 (w), 3090 (w), 2960 (m) , 2920 (m) , 2870 (w), 1712 (s), 1635 (s), 1595 (s) , 1575 (s) . IR spectrum: characteristic absorption bands were recorded at the following frequencies (in cm"<1>): 3430 (b), 3200 (w), 3090 (w), 2960 (m), 2920 (m), 2870 (w), 1712 (s), 1635 (s), 1595 (s) , 1575 (s) .
b = bred; w = svak; m = middels; s = sterk. b = wide; w = weak; m = medium; s = strong.
' H- MMR- spektrum; karakteristiske resonanstopper ble registrert ved følgende 6 (uttrykt i ppm): -0,63 (d, 3H); 0,12 (d, 3H); 0,77 (d, 3H); 0,93 (d, 3H); 1,89 (s, 3H); 1,94 (s, 3H); 1,99 ' H- MMR spectrum; characteristic resonance peaks were recorded at the following 6 (expressed in ppm): -0.63 (d, 3H); 0.12 (d, 3H); 0.77 (d, 3H); 0.93 (d, 3H); 1.89 (s, 3H); 1.94 (s, 3H); 1.99
(s, 3H); 2,24 (s, 3H); 2,83 (d, 1H); 2,94 (s, 3H); 3,25 (d, 1H) ; 3,57 (d, 1H); 3,30-4,00 (m, 2H); 4,82 (d, 1H); 4,96 (q, 1H); 5,97 (d, 1H); 5,80-6,96 (m, 3H); 7,74 (m, 2H); 8,51 (s, 1H); 8,62 (d, 1H); 15,56 (bred, s, 1H); 16,75 (s, 1H). (p, 3H); 2.24 (s, 3H); 2.83 (d, 1H); 2.94 (s, 3H); 3.25 (d, 1H); 3.57 (d, 1H); 3.30-4.00 (m, 2H); 4.82 (d, 1H); 4.96 (q, 1H); 5.97 (d, 1H); 5.80-6.96 (m, 3H); 7.74 (m, 2H); 8.51 (s, 1H); 8.62 (d, 1H); 15.56 (broad, p, 1H); 16.75 (p, 1H).
s = singlet; d = dublett; q = kvartett; m = multippel. s = singlet; d = doublet; q = quartet; m = multiple.
13 C- NMR- spektrum: karakteristiske resonanstopper ble registrert ved følgende 6 (uttrykt i ppm): 6,81; 7,73; 7,95; 10,05: 16,98; 20,02; 20 ,07 / •20,1 Q_; 32,57; 36,55; 37,60; 38,22; 56,78; 72,43; 73,36; 76,42; 77,33; 98,12; 103,52; 104,87; 108,99; 112,31; 115,24; 115,78; 120,98; 122,55; 123,31; 125,11; 127,00; 128,32; 144,62; 146,37; 147,18; 151,82; 151,98; 155,52; 170,78; 171,42; 171,74; 182,36; 187,79. 13 C-NMR spectrum: characteristic resonance peaks were recorded at the following δ (expressed in ppm): 6.81; 7.73; 7.95; 10.05: 16.98; 20.02; 20 .07 / •20.1 Q_; 32.57; 36.55; 37.60; 38.22; 56.78; 72.43; 73.36; 76.42; 77.33; 98.12; 103.52; 104.87; 108.99; 112.31; 115.24; 115.78; 120.98; 122.55; 123.31; 125.11; 127.00; 128.32; 144.62; 146.37; 147.18; 151.82; 151.98; 155.52; 170.78; 171.42; 171.74; 182.36; 187.79.
Eksempel 4 Example 4
3', 5'- dibrom- 4- deoksy- pyrido[ 1', 2' :1, 2] imidazot 5, 4- c] rifamycin SV 3', 5'- dibromo- 4- deoxy- pyrido[ 1', 2' :1, 2] imidazote 5, 4- c] rifamycin SV
Ved i det vesentlige å benytte fremgangsmåten beskrevet i Eksempel 1 og gå ut fra 1,39 g (0,002 mol) rifamycin S, 1,76 g (0,007 mol) 2-amino-3,5-dibrom-pyridin og 0,25 g (0,001 mol) By essentially using the method described in Example 1 and starting from 1.39 g (0.002 mol) rifamycin S, 1.76 g (0.007 mol) 2-amino-3,5-dibromo-pyridine and 0.25 g (0.001 mole)
jod i 15 ml metylenklorid, ble 1,35 g av tittelproduktet oppnådd i et utbytte på 71 % av det teoretiske. iodine in 15 ml of methylene chloride, 1.35 g of the title product was obtained in a yield of 71% of the theoretical.
Forbindelsen oppviste følgende fysikalsk-kjemiske karakteristika: The compound showed the following physico-chemical characteristics:
IR- spektrum: karakteristiske absorbsjonsbånd ble registrert ved følgende frekvenser (i cm"<1>): 3480 (b), 3350 (b), 3200 (w), 2980 (m), 2940 (m), 2880 (w), 1715 (s), 1650 (s), 1625 (m), 1600 (s), 1580 (m). IR spectrum: characteristic absorption bands were recorded at the following frequencies (in cm"<1>): 3480 (b), 3350 (b), 3200 (w), 2980 (m), 2940 (m), 2880 (w), 1715 (s), 1650 (s), 1625 (m), 1600 (s), 1580 (m).
b = bred; w = svak; m = middels; s = sterk. b = wide; w = weak; m = medium; s = strong.
H- NMR- spektrum: karakteristiske resonanstopper ble registrert H-NMR spectrum: characteristic resonance peaks were recorded
ved følgende 6 (uttrykt i ppm): -0,47 (d, 3H); 0,30 (d, 3H); at the following 6 (expressed in ppm): -0.47 (d, 3H); 0.30 (d, 3H);
0,80 (d, 3H); 0,98 (d, 3H); 1,96 (s, 6H); 1,99 (s, 3H); 2,25 0.80 (d, 3H); 0.98 (d, 3H); 1.96 (s, 6H); 1.99 (s, 3H); 2.25
(s, 3H); 2,88 (d, 1H); 3,03 (s, 3H); 3,20-4,00 (m, 4H); 4,87 (p, 3H); 2.88 (d, 1H); 3.03 (s, 3H); 3.20-4.00 (m, 4H); 4.87
(d, 1H); 5,11 (q, 1H); 6,12 (d, 1H); 6,00-7,00 (m, 3H); 7,94 (d, 1H); 5.11 (q, 1H); 6.12 (d, 1H); 6.00-7.00 (m, 3H); 7.94
(d, 1H); 8,52 (d, 1H); 15,48 (bred, s, 1H); 16,66 (bred, s, 1H). s = singlet; d = dublett; q = kvartett; m = multippel. (d, 1H); 8.52 (d, 1H); 15.48 (broad, p, 1H); 16.66 (broad, p, 1H). s = singlet; d = doublet; q = quartet; m = multiple.
1^ C- NMR- spektrum: karakteristiske resonanstopper ble registrert ved følgende 6 (uttrykt i ppm): 7,46; 7,89; 8,38; 11,92; 1^ C-NMR spectrum: characteristic resonance peaks were recorded at the following 6 (expressed in ppm): 7.46; 7.89; 8.38; 11.92;
18,22; 20,40; 21,07; 22,38; 33,19; 37,49; 38,94; 39,99; 40,71; 18.22; 20.40; 21.07; 22.38; 33.19; 37.49; 38.94; 39.99; 40.71;
56,37; 72,38; 73,01; 76,13; 76,42; 99,04; 104,07; 104,73; 56.37; 72.38; 73.01; 76.13; 76.42; 99.04; 104.07; 104.73;
107,40; 109,36; 110,35; 112,31; 116,29; 118,40; 121,77; 124,90; 107.40; 109.36; 110.35; 112.31; 116.29; 118.40; 121.77; 124.90;
126,20; 126,92; 130,56; 137,68; 138,62; 140,44; 141,82; 142,73; 126.20; 126.92; 130.56; 137.68; 138.62; 140.44; 141.82; 142.73;
157,29; 170,01; 170,72; 183,49; 185,85. 157.29; 170.01; 170.72; 183.49; 185.85.
Eksempel 5 Example 5
4- deoksy- isokinolino[ 2', 1' :1, 2] imidazot 5, 4- c] rifamycin SV 4- deoxy- isoquinolino[ 2', 1' :1, 2] imidazote 5, 4- c] rifamycin SV
Ved i det vesentlige å benytte fremgangsmåten beskrevet i Eksempel 2 og gå ut fra 6,95 g (0,01 mol) rifamycin S, 4,32 g (0,03 mol) 1-amino-isokinolin og 3,80 g (0,015 mol) jod, ble 5,9 g av tittelproduktet oppnådd i et utbytte på 72 % av det teoretiske. By essentially using the method described in Example 2 and starting from 6.95 g (0.01 mol) rifamycin S, 4.32 g (0.03 mol) 1-amino-isoquinoline and 3.80 g (0.015 mol) of iodine, 5.9 g of the title product were obtained in a yield of 72% of the theoretical.
Denne forbindelse oppviste følgende fysikalsk-kjemiske karakteristika: This compound showed the following physico-chemical characteristics:
Smeltepunkt: 181-186°C (dekomponering). Melting point: 181-186°C (decomposition).
IR- spektrum: karakteristiske absorbsjonsbånd ble registrert ved Jølgende frekvenser (i cm<-1>): 3440 (b), 3140 (b), 2910 (s), 2850 (w), 1700 (s), 1630 (b), 1610 (b), 1580 (w), 1555 (vw), 1535 (vw). IR spectrum: characteristic absorption bands were recorded at Roaring frequencies (in cm<-1>): 3440 (b), 3140 (b), 2910 (s), 2850 (w), 1700 (s), 1630 (b), 1610 (b), 1580 (w), 1555 (vw), 1535 (vw).
b = bred; s = sterk; w = svak; vw = meget svak. b = wide; s = strong; w = weak; vw = very weak.
1H- NMR- spektrum: karakteristiske resonanstopper ble registrert ved følgende 6 (uttrykt i ppm): -0,65 (d, 3H); 0,04 (d, 3H); 1 H-NMR spectrum: characteristic resonance peaks were recorded at the following 6 (expressed in ppm): -0.65 (d, 3H); 0.04 (d, 3H);
0,7 (d, 3H); 0,88 (d, 3H); 1,55 (s, 3H); 1,92 (s, 3H); 2,02 0.7 (d, 3H); 0.88 (d, 3H); 1.55 (s, 3H); 1.92 (s, 3H); 2.02
(s, 3H); 2,27 (s, 3H); 2,77 (d, 1H); 2,94 (s, 3H); 3,00-3,90 (p, 3H); 2.27 (s, 3H); 2.77 (d, 1H); 2.94 (s, 3H); 3.00-3.90
(m, 4H); 4,78 (d, 1H); 4,93 (q, 1H); 5,75-7,00 (m, 4H); 7,34 (m, 4H); 4.78 (d, 1H); 4.93 (q, 1H); 5.75-7.00 (m, 4H); 7.34
(d, 1H); 7,6-8,0 (m, 6H); 16,6 (m, 1H). (d, 1H); 7.6-8.0 (m, 6H); 16.6 (m, 1H).
s = singlet; d = dublett; m = multippel; q = kvartett. s = singlet; d = doublet; m = multiple; q = quartet.
Eksempel 6 Example 6
3', 5'- diklor- 4- deoksy- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4- c] - rifamycin SV 3', 5'- dichloro- 4- deoxy- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4-c] - rifamycin SV
Ved i det vesentlige å benytte fremgangsmåten beskrevet i Eksempel 2 og gå ut fra 4,9 g (0,007 mol) rifamycin S, 3,42 g (0,021 mol) 2-amino-3,5-diklorpyridin og 2,66 g (0,0105 mol) jod, ble 4 g av tittelforbindelsen oppnådd i et utbytte på 67 % By essentially using the method described in Example 2 and starting from 4.9 g (0.007 mol) rifamycin S, 3.42 g (0.021 mol) 2-amino-3,5-dichloropyridine and 2.66 g (0 .0105 mol) of iodine, 4 g of the title compound were obtained in a yield of 67%
av det teoretiske. of the theoretical.
Denne forbindelsen oppviste følgende fysikalsk-kjemiske karakteristika: This compound showed the following physico-chemical characteristics:
IR- spektrum: karakteristiske absorbsjonsbånd ble registrert ved følgende frekvenser (i cm<-1>): 3450 (b), 3250 (w), 2970 (m), 2930 (m), 2880 (m), 1710 (s), 1640 (s), 1585 (s). IR spectrum: characteristic absorption bands were recorded at the following frequencies (in cm<-1>): 3450 (b), 3250 (w), 2970 (m), 2930 (m), 2880 (m), 1710 (s), 1640 (p), 1585 (p).
b = bred; m = middels; w = svak; s = sterk. b = wide; m = medium; w = weak; s = strong.
1H- NMR- spektrum: karakteristiske resonanstopper ble registrert ved følgende 6 (uttrykt i ppm): -0,56 (d, 3H); 0,23 (d, 3H); 0,78 (d, 3H); 0,94 (d, 3H); 1,92 (s, 3H); 1,97 (s, 6H); 2,25 (s, 3H); 2,70-3,00 (m, 1H); 2,98 (s, 3H); 3,10-3,80 (m, 4H); 4,84 (d, 1H); 5,05 (q, 1H); 6,03 (d, 1H); 6,00-7,00 (m, 3H); 7,18 (s, 1H); 8,13 (s, 1H); 8,35 (s, 1H); 16,00 (bred, s, 1H); 16,45 (stor, s, 1H). 1 H-NMR spectrum: characteristic resonance peaks were recorded at the following 6 (expressed in ppm): -0.56 (d, 3H); 0.23 (d, 3H); 0.78 (d, 3H); 0.94 (d, 3H); 1.92 (s, 3H); 1.97 (s, 6H); 2.25 (s, 3H); 2.70-3.00 (m, 1H); 2.98 (s, 3H); 3.10-3.80 (m, 4H); 4.84 (d, 1H); 5.05 (q, 1H); 6.03 (d, 1H); 6.00-7.00 (m, 3H); 7.18 (s, 1H); 8.13 (s, 1H); 8.35 (s, 1H); 16.00 (broad, p, 1H); 16.45 (large, p, 1H).
s = singlet; d = dublett; q = kvartett; m = multippel. s = singlet; d = doublet; q = quartet; m = multiple.
13C- NMR- spektrum: karakteristiske resonanstopper ble registrert ved følgende 6 (uttrykt i ppm): 7,03; 8,34; 8,58; 11,08; 17,53; 20,54; 20,88; 21,82; 33,41; 37,23; 38,25; 38,69; 57,16; 74,17; 77,16; 78,14; 78,76; 99,49; 105,59; 106,15; 110,52; 112,50; 116,80; 116,95; 119,97; 121,23; 124,96; 125,57; 125,62; 126,00; 128,45;132,03;137,53;138,06;142,07; 142,83; 155,15; 170,74; 170,96; 172,21; 181,66; 184,91. 13 C-NMR spectrum: characteristic resonance peaks were recorded at the following δ (expressed in ppm): 7.03; 8.34; 8.58; 11.08; 17.53; 20.54; 20.88; 21.82; 33.41; 37.23; 38.25; 38.69; 57.16; 74.17; 77.16; 78.14; 78.76; 99.49; 105.59; 106.15; 110.52; 112.50; 116.80; 116.95; 119.97; 121.23; 124.96; 125.57; 125.62; 126.00; 128.45;132.03;137.53;138.06;142.07; 142.83; 155.15; 170.74; 170.96; 172.21; 181.66; 184.91.
Eksempel 7 Example 7
4- deoksy- 4'- metyl- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4- c] rifamycin SV 4- deoxy- 4'- methyl- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4-c] rifamycin SV
En oppløsning av 6,95 g (0,01 mol) rifamycin S og 3,24 g (0,03 mol) 2-amino-4-metyl-pyridin i 20 ml acetonitril ble porsjonsvis tilsatt 3,80 g (0,015 mol) jod i løpet av 1 time, hvorpå reaksjonen ble fortsatt i ytterligere 6 timer under omrøring ved romtemperatur. Reaksjonsblandingen ble deretter tilsatt 20 ml av en 20 % (vekt/volum) vandig oppløsning av ascorbinsyre og omrørt i 30 minutter til. Deretter ble 5 ml eddiksyre og 25 ml 0,1N vandig saltsyreoppløsning tilsatt og reaksjonsblandingen satt tilside over natten ved 5°C. Det utkrystalliserte faststoff ble frafiltrert og tørket og ga 5,1 g produkt i et utbytte på 6 5 % av det teoretiske. Den oppnådde forbindelse hadde de samme fysikalsk-kjemiske karakteristika som produktet i Eksempel 1. A solution of 6.95 g (0.01 mol) rifamycin S and 3.24 g (0.03 mol) 2-amino-4-methyl-pyridine in 20 ml acetonitrile was added portionwise to 3.80 g (0.015 mol) iodine over 1 hour, after which the reaction was continued for a further 6 hours under stirring at room temperature. To the reaction mixture was then added 20 ml of a 20% (w/v) aqueous solution of ascorbic acid and stirred for a further 30 minutes. Then 5 ml of acetic acid and 25 ml of 0.1N aqueous hydrochloric acid solution were added and the reaction mixture was set aside overnight at 5°C. The crystallized solid was filtered off and dried and gave 5.1 g of product in a yield of 65% of the theoretical. The compound obtained had the same physicochemical characteristics as the product in Example 1.
Eksempel- 8 Example- 8
4- deoksy- 4'- metyl- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4- c] rifamycin SV 4- deoxy- 4'- methyl- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4-c] rifamycin SV
En oppløsning av 4,9 g (0,007 mol) rifamycin S, 3 g A solution of 4.9 g (0.007 mol) rifamycin S, 3 g
(0,028 mol) 2-amino-4-metyl-pyridin og 3 g (0,012 mol) jod i (0.028 mol) 2-amino-4-methyl-pyridine and 3 g (0.012 mol) iodine in
3 0 ml metylenklorid, ble oppvarmet til reaksjonsblandingens kokepunkt i 1 time. Etter avkjøling til romtemperatur ble opp-løsningen tilsatt 20 ml av en 25 % (vekt/volum) vandig opp-løsning av ascorbinsyre og omrørt i 30 minutter. De to lagene ble separert og den organiske fase vasket to ganger med 30 ml 1N saltsyre og deretter med vann inntil nøytral reaksjon og deretter tørket over natriumsulfat. Etter filtrering og for dampning av oppløsningsmidlet, ble det oppnådd et residuum som ble omkrystallisert fra en blanding av etanol/vann, 7:3 (volumdeler) for å gi 4,4 g produkt i et utbytte på 80 % av 30 ml of methylene chloride, was heated to the boiling point of the reaction mixture for 1 hour. After cooling to room temperature, 20 ml of a 25% (w/v) aqueous solution of ascorbic acid was added to the solution and stirred for 30 minutes. The two layers were separated and the organic phase washed twice with 30 ml of 1N hydrochloric acid and then with water until a neutral reaction and then dried over sodium sulfate. After filtration and evaporation of the solvent, a residue was obtained which was recrystallized from a mixture of ethanol/water, 7:3 (v/v) to give 4.4 g of product in an 80% yield of
det teoretiske. Forbindelsen hadde de samme fysikalsk-kjemiske karakteristika som produktet fra Eksempel 1. the theoretical. The compound had the same physicochemical characteristics as the product from Example 1.
Eksempel 9 Example 9
4- deoksy- 5'- metyl- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4- c] rifamycin SV 4- deoxy- 5'- methyl- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4-c] rifamycin SV
En oppløsning av 4,9 g (0,007 mol) rifamycin S, 3 g (0,028 mol) 2-amino-3-metyl-pyridin, 3,3 g (0,014 mol) 2-amino-3-metyl-pyridin-hydrojodid og 1,8 g (0,0071 mol) jod i 35 ml metylenklorid, ble oppvarmet til reaksjonsblandingens kokepunkt i 4 timer. Etter avkjøling ble oppløsningen tilsatt 10 ml av en 25 % (vekt/volum) vandig oppløsning av ascorbinsyre og omrørt i 30 minutter. De to lagene ble separert og den organiske fase vasket to ganger med 30 ml 1N vandig saltsyre og deretter med vann inntil nøytral reaksjon, og deretter tørket over natriumsulfat. Etter filtrering og fordampning av oppløsnings-midlet, ble det oppnådd et residuum som ble omkrystallisert fra en blanding av etanol/vann, 7:3 (volumdeler), hvorved det ble oppnådd 4,1 g produkt i et utbytte på 75 % av det teoretiske. A solution of 4.9 g (0.007 mol) rifamycin S, 3 g (0.028 mol) 2-amino-3-methyl-pyridine, 3.3 g (0.014 mol) 2-amino-3-methyl-pyridine hydroiodide and 1.8 g (0.0071 mol) of iodine in 35 ml of methylene chloride was heated to the boiling point of the reaction mixture for 4 hours. After cooling, the solution was added to 10 ml of a 25% (w/v) aqueous solution of ascorbic acid and stirred for 30 minutes. The two layers were separated and the organic phase washed twice with 30 ml of 1N aqueous hydrochloric acid and then with water until neutral reaction, and then dried over sodium sulfate. After filtration and evaporation of the solvent, a residue was obtained which was recrystallized from a mixture of ethanol/water, 7:3 (parts by volume), whereby 4.1 g of product was obtained in a yield of 75% of the theoretical .
Produktet hadde følgende fysikalsk-kjemiske karakteristika: Smeltepunkt: 185-190°C (dekomponering). The product had the following physico-chemical characteristics: Melting point: 185-190°C (decomposition).
IR-spektrum: karakteristiske absorbsjonsbånd ble registrert ved følgende frekvenser (i cm<-1>): 3440 (b), 3300 (b), 3200 (b), 2960 (s), 2920 (w), 2850 (vw), 1730 (s), 1710 (w), 1640 (s), 1595 (s), 1580 (b), 1555 (w). IR spectrum: characteristic absorption bands were recorded at the following frequencies (in cm<-1>): 3440 (b), 3300 (b), 3200 (b), 2960 (s), 2920 (w), 2850 (vw), 1730 (s), 1710 (w), 1640 (s), 1595 (s), 1580 (b), 1555 (w).
b = bred; s = sterk; w = svak; vw = meget svak. b = wide; s = strong; w = weak; vw = very weak.
1H- NMR- spektrum; karakteristiske resonanstopper ble registrert ved følgende 6 (uttrykt i ppm): -0,64 (d, 3H); 0,02 (d, 3H); 0,45 (d, 3H); 0,90 (d, 3H); 1,75 (s, 3H); 1,94 (s, 3H); 1,97 (s, 3H); 2,23 (s, 3H); 2,45 (s, 3H); 2,95 (s, 3H); 2,6-5,8 1H-NMR spectrum; characteristic resonance peaks were recorded at the following 6 (expressed in ppm): -0.64 (d, 3H); 0.02 (d, 3H); 0.45 (d, 3H); 0.90 (d, 3H); 1.75 (s, 3H); 1.94 (s, 3H); 1.97 (s, 3H); 2.23 (s, 3H); 2.45 (s, 3H); 2.95 (s, 3H); 2.6-5.8
(m, 5H); 4,5-5,25 (m, 2H); 5,5-7,0 (m, 4H); 7,25-7,75 (m, 2H); 8,27 (s, 1H); 8,47 (s, 1H); 14,86 (s, 1H); 16,77 (s, 1H). (m, 5H); 4.5-5.25 (m, 2H); 5.5-7.0 (m, 4H); 7.25-7.75 (m, 2H); 8.27 (s, 1H); 8.47 (s, 1H); 14.86 (s, 1H); 16.77 (p, 1H).
Eksempel 10 Example 10
4- deoksy-4'- metyl- pyrido[ 1', 2' :1, 2] imidazol5, 4- c] rifamycin SV 4- deoxy-4'- methyl- pyrido[1', 2' :1, 2] imidazole5, 4-c] rifamycin SV
En oppløsning av 6,95 g (0,01 mol) rifamycin S, 4,32 g (0,04 mol) 2-amino-4-metyl-pyridin, 2,4.g (0,04 mol) eddiksyre og 0,25 g (0,001 mol) jod i 40 ml metylenklorid ble holdt ved romtemperatur i 5 dager. Reaksjonsblandingen ble deretter tilsatt 0,37 g (0,002 mol) ascorbinsyre og omrørt i 30 minutter. Den ble deretter vasket med en 0,5N vandig saltsyreoppløsning og deretter med vann, hvorpå den tilslutt ble inndampet til tørrhet under redusert trykk. Residuet ble omkrystallisert fra en blanding av etanol/vann, 7:3 (volumdeler), hvorved 5,74 g produkt ble oppnådd i et utbytte på 73 % av det teoretiske. A solution of 6.95 g (0.01 mol) rifamycin S, 4.32 g (0.04 mol) 2-amino-4-methyl-pyridine, 2.4 g (0.04 mol) acetic acid and 0 .25 g (0.001 mol) of iodine in 40 ml of methylene chloride was kept at room temperature for 5 days. The reaction mixture was then added with 0.37 g (0.002 mol) of ascorbic acid and stirred for 30 minutes. It was then washed with a 0.5N aqueous hydrochloric acid solution and then with water, after which it was finally evaporated to dryness under reduced pressure. The residue was recrystallized from a mixture of ethanol/water, 7:3 (parts by volume), whereby 5.74 g of product was obtained in a yield of 73% of the theoretical.
Produktet hadde samme fysikalsk-kjemiske karakteristika som produktet fra Eksempel 1. The product had the same physico-chemical characteristics as the product from Example 1.
Eksempel 11 Example 11
4- deoksy- 4'- metyl- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4- c] rifamycin SV 4- deoxy- 4'- methyl- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4-c] rifamycin SV
En oppløsning av 4,9 g (0,007 mol) rifamycin S, 3 g A solution of 4.9 g (0.007 mol) rifamycin S, 3 g
(0,028 mol) 2-amino-4-metyl-pyridin, 0,45 g (0,0018 mol) jod og 1,65 ml (0,029 mol) eddiksyre i 15 ml acetonitril, ble holdt ved romtemperatur i 48 timer. Reaksjonsblandingen ble deretter tilsatt ytterligere 0,2 g (0,0008 mol) jod og holdt ved romtemperatur i 16 timer til. Den ble deretter tilsatt 3 ml av en 2 5 % (vekt/volum) vandig oppløsning av ascorbinsyre og, etter ytterligere 30 minutter, fortynnet med 85 ml metylenklorid. Den organiske oppløsning ble vasket to ganger med 30 ml IN vandig saltsyreoppløsning og deretter med vann inntil (0.028 mol) of 2-amino-4-methyl-pyridine, 0.45 g (0.0018 mol) of iodine and 1.65 ml (0.029 mol) of acetic acid in 15 ml of acetonitrile were kept at room temperature for 48 hours. An additional 0.2 g (0.0008 mol) of iodine was then added to the reaction mixture and kept at room temperature for another 16 hours. To it was then added 3 ml of a 25% (w/v) aqueous solution of ascorbic acid and, after a further 30 minutes, diluted with 85 ml of methylene chloride. The organic solution was washed twice with 30 ml of 1N aqueous hydrochloric acid solution and then with water until
nøytral reaksjon, og tørket over natriumsulfat. Etter filtrering og fordampning av oppløsningsmidlet under vakuum, ble det oppnådd et residuum som ble omkrystallisert fra en blanding av etanol/vann, 7:3 (volumdeler), hvorved 4,2 g av produktet ble oppnådd i et utbytte på 77 % av det teoretiske. neutral reaction, and dried over sodium sulfate. After filtration and evaporation of the solvent under vacuum, a residue was obtained which was recrystallized from a mixture of ethanol/water, 7:3 (parts by volume), whereby 4.2 g of the product was obtained in a yield of 77% of the theoretical .
Produktet hadde samme fysikalsk-kjemiske karakteristika som produktet beskrevet i Eksempel 1. The product had the same physico-chemical characteristics as the product described in Example 1.
Eksempel 12 Example 12
4- deoksy- 4'- metyl- pyrido[ 1', 2' :1, 2] imidazoC 5, 4- c] rifamycin SV 4- deoxy- 4'- methyl- pyrido[ 1', 2' :1, 2] imidazoC 5, 4- c] rifamycin SV
4,9 g (0,007 mol) rifamycin S, 3 g (0,028 mol) 2-amino-4-metyl-pyridin, 3,3 g (0,014 mol) 2-amino-4-metyl-pyridin-hydrojodid og 0,89 g (0,0035 mol) jod, ble løst opp i 20 ml 4.9 g (0.007 mol) rifamycin S, 3 g (0.028 mol) 2-amino-4-methyl-pyridine, 3.3 g (0.014 mol) 2-amino-4-methyl-pyridine hydroiodide and 0.89 g (0.0035 mol) of iodine was dissolved in 20 ml
dimetoksyetan og reaksjonsblandingen hensatt ved romtemperatur i 20 timer. Reaksjonsblandingen ble deretter tilsatt 5 ml av en 25 % (vekt/volum) vandig oppløsning av ascorbinsyre og omrørt i 30 minutter. Reaksjonsblandingén ble deretter fortynnet med 100 ml metylenklorid, vasket to ganger med 30 ml 1N vandig saltsyreoppløsning og deretter med vann til nøytral reaksjon. Den organiske fase ble tørket over vannfri natriumsulfat og filtrert, hvorpå oppløsningsmidlet ble fordampet. dimethoxyethane and the reaction mixture left at room temperature for 20 hours. To the reaction mixture was then added 5 ml of a 25% (w/v) aqueous solution of ascorbic acid and stirred for 30 minutes. The reaction mixture was then diluted with 100 ml of methylene chloride, washed twice with 30 ml of 1N aqueous hydrochloric acid solution and then with water to neutral reaction. The organic phase was dried over anhydrous sodium sulfate and filtered, after which the solvent was evaporated.
Residuet ble omkrystallisert fra en blanding av etanol og vann, 7:3 (volumdeler), hvorved 3,7 g produkt ble oppnådd i et utbytte på 68 % av det teoretiske. Dette hadde de samme fysikalsk-kjemiske karakteristika som produktet beskrevet i Eksempel 1. The residue was recrystallized from a mixture of ethanol and water, 7:3 (parts by volume), whereby 3.7 g of product was obtained in a yield of 68% of the theoretical. This had the same physico-chemical characteristics as the product described in Example 1.
Eksempel 13 Example 13
4- deoksy- 4'- metyl- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4- c] rifamycin SV 4- deoxy- 4'- methyl- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4-c] rifamycin SV
696 g (1 mol) rifamycin S, 324 g (3 mol) 2-amino-4-metyl-pyridin og 127 g (0,5 mol) jod, ble løst opp i 3 liter metylenklorid og reaksjonsblandingén holdt ved romtemperatur i 24 timer. Den ble deretter tilsatt 0,5 liter av en 20 % 696 g (1 mol) rifamycin S, 324 g (3 mol) 2-amino-4-methyl-pyridine and 127 g (0.5 mol) iodine were dissolved in 3 liters of methylene chloride and the reaction mixture was kept at room temperature for 24 hours . It was then added 0.5 liters of a 20%
(vekt/volum) vandig oppløsning av ascorbinsyre og omrørt i 1 time. Den vandige fase ble helt av og den organiske fase vasket tre ganger med 1 liter 1N vandig saltsyreoppløsning (weight/volume) aqueous solution of ascorbic acid and stirred for 1 hour. The aqueous phase was poured off and the organic phase was washed three times with 1 liter of 1N aqueous hydrochloric acid solution
for å fjerne uomsatt overskudd av 2-amino-4-metyl-pyridin, og deretter med vann inntil nøytral reaksjon, og deretter inndampet til tørrhet under vakuum. Det faste residuum ble omkrystallisert fra en blanding av etanol/vann, 7:3 (volumdeler), hvorved 613 g produkt ble oppnådd i et utbytte på 78 % av det teoretiske. to remove unreacted excess of 2-amino-4-methyl-pyridine, and then with water until neutral reaction, and then evaporated to dryness under vacuum. The solid residue was recrystallized from a mixture of ethanol/water, 7:3 (parts by volume), whereby 613 g of product was obtained in a yield of 78% of the theoretical.
Det således oppnådde produkt oppviste de samme fysikalsk-kjemiske karakteristika som produktet beskrevet i Eksempel 1. The product thus obtained exhibited the same physico-chemical characteristics as the product described in Example 1.
Eksempel 14 Example 14
4'- deoksy- 4'- metyl- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4- c] rifamycin SV 4'- deoxy- 4'- methyl- pyrido[ 1', 2' :1, 2] imidazo[ 5, 4-c] rifamycin SV
487 g (0,7 mol) rifamycin S, 303 g (2,8 mol) 2-amino-4-metyl-pyridin og 254 g (1 mol) jod, ble løst opp i 3 liter metylenklorid og reaksjonsblandingén holdt ved romtemperatur i 4 timer. Den ble deretter tilsatt 1,5 liter 25 % (vekt/volum) vandig ascorbinsyreoppløsning og omrørt i 30 minutter. Den vandige fase ble kassert, den organiske fase vasket fire ganger med 1 liter 1N vandig saltsyreoppløsning for å fjerne uomsatt overskudd av 2-amino-4-metyl-pyridin og deretter vasket med vann inntil nøytral reaksjon og tilslutt tørket over natrium-sulf at. Etter filtrering og fordampning av oppløsningsmidlet, ble det oppnådd et residuum som ble omkrystallisert fra en blanding av etanol/vann, 7:3 (volumdeler), hvorved 440 g produkt ble oppnådd i et utbytte på 80 % av det teoretiske. 487 g (0.7 mol) rifamycin S, 303 g (2.8 mol) 2-amino-4-methyl-pyridine and 254 g (1 mol) iodine were dissolved in 3 liters of methylene chloride and the reaction mixture was kept at room temperature for 4 hours. It was then added to 1.5 liters of 25% (w/v) aqueous ascorbic acid solution and stirred for 30 minutes. The aqueous phase was discarded, the organic phase washed four times with 1 liter of 1N aqueous hydrochloric acid solution to remove unreacted excess of 2-amino-4-methyl-pyridine and then washed with water until a neutral reaction and finally dried over sodium sulfate. After filtration and evaporation of the solvent, a residue was obtained which was recrystallized from a mixture of ethanol/water, 7:3 (parts by volume), whereby 440 g of product was obtained in a yield of 80% of the theoretical.
Det således oppnådde produkt oppviste de samme fysikalsk-kjemiske karakteristika som produktet beskrevet i Eksempel 1. The product thus obtained exhibited the same physico-chemical characteristics as the product described in Example 1.
Claims (3)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT03465/84A IT1199376B (en) | 1984-05-15 | 1984-05-15 | IMIDAZO-RIFAMICINE PREPARATION PROCESS |
IT03464/84A IT1199375B (en) | 1984-05-15 | 1984-05-15 | PROCESS FOR THE PREPARATION OF IMIDAZO RIFAMICINE |
Publications (3)
Publication Number | Publication Date |
---|---|
NO851920L NO851920L (en) | 1985-11-18 |
NO164030B true NO164030B (en) | 1990-05-14 |
NO164030C NO164030C (en) | 1990-08-22 |
Family
ID=26325399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO851920A NO164030C (en) | 1984-05-15 | 1985-05-14 | PROCEDURE FOR THE PREPARATION OF IMIDAZO-RIFAMYCIN DERIVATIVES. |
Country Status (9)
Country | Link |
---|---|
AR (1) | AR242795A1 (en) |
AT (1) | AT386829B (en) |
CA (1) | CA1215976A (en) |
DK (1) | DK160829C (en) |
ES (1) | ES543116A0 (en) |
FI (1) | FI83874C (en) |
GR (1) | GR851146B (en) |
NO (1) | NO164030C (en) |
PT (1) | PT80447B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20032144A1 (en) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | REFLEXIMINE POLIMORPHIC FORMS, PROCESSES TO OBTAIN THEM AND |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
PL1698630T3 (en) | 2005-03-03 | 2014-12-31 | Alfasigma Spa | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
AU2007298733B2 (en) | 2006-09-22 | 2012-11-08 | Cipla Limited | Rifaximin |
US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
KR20110107806A (en) | 2008-12-10 | 2011-10-04 | 시플라 리미티드 | Rifaximin complexes |
ITBO20120368A1 (en) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | COMPOSITIONS INCLUDING RIFAXIMINA AND AMINO ACIDS, RIFAXIMINE CRYSTALS DERIVING FROM SUCH COMPOSITIONS AND THEIR USE. |
ES2621557T3 (en) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Polymorphic mixture of rifaximin and its use for the preparation of solid formulations |
WO2015159275A2 (en) * | 2014-04-19 | 2015-10-22 | Granules India Limited | An improved process for the preparation of rifamycin derivatives |
AU2015260837B2 (en) | 2014-05-12 | 2019-02-28 | Alfasigma S.P.A. | New solvated crystal form of rifaximin, production, compositions and uses thereof |
-
1985
- 1985-04-29 CA CA000480320A patent/CA1215976A/en not_active Expired
- 1985-05-13 PT PT8044785A patent/PT80447B/en unknown
- 1985-05-13 GR GR851146A patent/GR851146B/el unknown
- 1985-05-14 DK DK214585A patent/DK160829C/en not_active IP Right Cessation
- 1985-05-14 NO NO851920A patent/NO164030C/en unknown
- 1985-05-14 AT AT145085A patent/AT386829B/en not_active IP Right Cessation
- 1985-05-14 ES ES543116A patent/ES543116A0/en active Granted
- 1985-05-14 FI FI851908A patent/FI83874C/en not_active IP Right Cessation
- 1985-05-15 AR AR30038685A patent/AR242795A1/en active
Also Published As
Publication number | Publication date |
---|---|
CA1215976A (en) | 1986-12-30 |
AT386829B (en) | 1988-10-25 |
NO851920L (en) | 1985-11-18 |
DK160829C (en) | 1991-10-07 |
DK214585D0 (en) | 1985-05-14 |
DK214585A (en) | 1985-11-16 |
DK160829B (en) | 1991-04-22 |
FI83874C (en) | 1991-09-10 |
FI851908L (en) | 1985-11-16 |
FI83874B (en) | 1991-05-31 |
FI851908A0 (en) | 1985-05-14 |
PT80447B (en) | 1987-11-11 |
ATA145085A (en) | 1988-03-15 |
ES8603490A1 (en) | 1986-01-01 |
ES543116A0 (en) | 1986-01-01 |
PT80447A (en) | 1985-06-01 |
GR851146B (en) | 1985-11-25 |
NO164030C (en) | 1990-08-22 |
AR242795A1 (en) | 1993-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4557866A (en) | Process for the synthesis of pyrido-imidazo rifamycins | |
NO164030B (en) | PROCEDURE TE FOR PREPARING IMIDAZO RIFAMYCINTER. | |
NO165998B (en) | PROCEDURE FOR THE PROTECTION OF AN ALLYLESTER OF A CARBAPENE MEMORANDUM. | |
NO157699B (en) | PROCEDURE FOR THE PREPARATION OF KINOLIN CARBOXYLIC ACID DERIVATIVES. | |
FI83875C (en) | ETT NYTT FOERFARANDE FOER FRAMSTAELLNING AV 4-DEOXIPYRIDO / 1'2 ': 1,2 / IMIDAZO / 5,4-C / RIFAMYCINER. | |
US4127575A (en) | Preparation of chloro substituted pyridines | |
JP3268530B2 (en) | Aqueous process for producing 5-methyl-N- (aryl) -1,2,4-triazolo [1,5-a] pyrimidine-2-sulfonamide | |
US5382671A (en) | Process for the preparation of 2-chloro-5-alkylaminomethyl-pyridines | |
US4031108A (en) | 2-Hydroxymethyl-3-benzyloxypyridine-6-epoxyethane | |
US6545149B2 (en) | Synthesis and crystallization of piperazine ring-containing compounds | |
FI62098B (en) | FREQUENCY REFRIGERATION OF THIAZOLO (5,4-C) RIFAMYCIN SV OCH DESS DERIVAT | |
Armarego et al. | Synthesis and stability of 2-methyl-2, 4-diaza-and 2-methyl-2, 5-diaza-indene (2-methyl-pyrrolo [3, 4-b] pyridine and-pyrrolo [3, 4-c] pyridine) | |
GB2025395A (en) | Therapeutically active substituted dibenzyl ethers | |
US3471506A (en) | Process for preparing 5-chloro-2,3-pyridine diol | |
JP2002524447A (en) | Chemical process for preparing 2-hydroxy-6-trifluoromethylpyridine | |
US20020068829A1 (en) | Process of preparing 3S-3-amino-3-aryl proprionic acid and derivatives thereof | |
CA2101789A1 (en) | Process for the preparation of imidazopyridines | |
US3364198A (en) | Process for the production of n6-methyltubercidin and intermediate | |
NarasimhaáRao | Oxidative demethylation of 4-substituted N, N-dimethylanilines with iodine and calcium oxide in the presence of methanol | |
US3361753A (en) | Certain 9-(3-pyridyl)thioxanthene and thioxanthol derivatives | |
US3115518A (en) | Production of cyclohexylideneaminooxyacetic acid, its esters, and its salts | |
US4033975A (en) | Process for the production of 2-amino-3-hydroxypyridine derivatives | |
NO863769L (en) | PROCEDURE FOR THE PREPARATION OF 4-HYDROXY-2-OXOPYRROLIN-1-YL-ACETAMIDE. | |
SU525429A3 (en) | The method of obtaining derivatives of 3-oxyiminomethyl cephalosporin or their salts | |
US4521603A (en) | Continuous process for the production of polybromopyridine compounds |